Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Thyroid Cancer
100%
Cell Adhesion
100%
Vascular Cells
100%
BRAF mutant
100%
Vemurafenib
100%
Thyroid Cancer Cells
37%
BRAF Inhibition
37%
IC50 Value
25%
Thyroid Cancer Cell Lines
25%
RNA-seq Analysis
12%
Dose Effect
12%
Co-treatment
12%
Antitumor Effect
12%
Mammalian Target of Rapamycin (mTOR)
12%
AKT Pathway
12%
Overexpression
12%
Knockdown
12%
Metastatic Melanoma
12%
Cell Apoptosis
12%
Anticancer Agents
12%
PI3K-AKT-mTOR Pathway
12%
Apoptosis Assay
12%
Thyroid Patients
12%
Induced Expression
12%
Papillary Thyroid Cancer
12%
Anaplastic Thyroid Cancer
12%
Cell Cytotoxicity Assay
12%
Signal Transduction Inhibitors
12%
Mutant BRAF
12%
MK-2206
12%
Vemurafenib Resistance
12%
BCPAP Cells
12%
BCPAP
12%
Biochemistry, Genetics and Molecular Biology
Upregulation
100%
Cell Adhesion
100%
Vemurafenib
100%
Cancer Cell
62%
IC50
25%
Mammalian Target of Rapamycin
25%
Protein Kinase B
25%
Anticancer
12%
Apoptosis Assay
12%
RNA Sequence
12%
Akt Signaling
12%
Cytotoxicity Assay
12%
Pharmacology, Toxicology and Pharmaceutical Science
Thyroid Cancer
100%
Vemurafenib
100%
IC50
25%
Anticarcinogen
12%
Cytotoxicity Assay
12%
Thyroid Papillary Carcinoma
12%
Metastatic Melanoma
12%
Anaplastic Thyroid Carcinoma
12%
RNA-Sequencing
12%
8 [4 (1 Aminocyclobutyl)phenyl] 9 Phenyl 1,2,4 triazolo[3,4 f][1,6]naphthyridin 3(2h) One
12%
Apoptosis Assay
12%